Is COVID-19 Coagulopathy a Thrombotic Microangiopathy? A Prospective, Observational Study
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26115395 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Mauro Silingardi und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Ospedale Maggiore "Carlo Alberto Pizzardi", 40133 Bologna, Italy. Hauptthemen laut MEDLINE: COVID-19, Thrombotic Microangiopathies, Blood Coagulation Disorders. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Siemens, Thermofisher, Werfen.
Abstract (Originalsprache)
Severe COVID-19 is often associated with coagulopathy and thrombotic complications. The underlying mechanisms are complex and multifactorial, involving platelet activation, dysregulation of the complement cascade, fibrinolytic imbalance, release of pro-inflammatory cytokines, immunothrombosis, antiphospholipid antibodies, and alterations in the von Willebrand factor (vWF)/ADAMTS13 axis. These pathways are also implicated in thrombotic microangiopathies (TMAs), characterized by endothelial injury and widespread microvascular thrombosis. In this prospective monocentric observational study, we investigated whether COVID-19-associated coagulopathy meets the criteria for TMA and evaluated the roles of complement activation and vWF/ADAMTS13 imbalance in disease severity. Forty-three hospitalized COVID-19 patients were enrolled and stratified by disease severity. Blood samples collected at admission were analyzed for hematologic, coagulation, inflammatory, and complement parameters. A 30-day follow-up recorded survival and thrombotic events. All patients showed elevated vWF and factor VIII levels; however, only vWF collagen-binding activity (vWF-CBA) significantly correlated with disease severity. ADAMTS13 activity remained above 60% in all cases, and no schistocytes were detected, arguing against a diagnosis of classical TMA. Nevertheless, the vWF-CBA/ADAMTS13 ratio was significantly higher in severe cases, particularly in unvaccinated individuals, suggesting endothelial dysregulation. Complement analysis revealed increased C5a levels and decreased C3b/iC3b ratios in severe disease, consistent with complement activation and consumption. C2 levels were also lower in these patients. Although complement activation and vWF/ADAMTS13 imbalance did not directly correlate, both pathways showed a similar trend according to disease severity. Overall, our findings indicate that COVID-19-related coagulopathy does not fulfill the criteria for classical TMA but shows features of complement-mediated endothelial injury and vWF dysregulation. The vWF-CBA may serve as a rapid, standardized tool for assessing endothelial dysfunction. Activation of the complement system, particularly via the lectin and alternative pathways, appears central to the prothrombotic state in severe COVID-19.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Ospedale Maggiore "Carlo Alberto Pizzardi", 40133 Bologna, Italy.
- Nephrology, Dialysis and Kidney Transplant Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy.
- Biostatistics, Department of Medical and Surgical Sciences (DIMEC), Alma Mater Studiorum-University of Bologna, 40138 Bologna, Italy.
- Department of Medical and Surgical Sciences (DIMEC), Alma Mater Studiorum-University of Bologna, 40138 Bologna, Italy.
- Department of Anaesthesia, Intensive Care and EMS, Ospedale Maggiore "Carlo Alberto Pizzardi", 40133 Bologna, Italy.
- Laboratorio Unico Metropolitano, AUSL Bologna, 40133 Bologna, Italy.
ORCID-Profile: Mauro Silingardi, Fulvia Zappulo, Chiara Donadei, Valeria Pizzuti, Gaetano La Manna, Giorgia Comai
Förderung
- Siemens
- Thermofisher
- Werfen
- Siemens Healthcare
- ThermoFisher Scientific
- Wefern
Zitieren
APA
Silingardi, M., Zappulo, F., Dormi, A., Pizzini, A. M., Donadei, C., Cappuccilli, M., Fantoni, C., Zaccaroni, S., Pizzuti, V., Cilloni, N., Tantillo, S., Guidi, A., Mancini, R., La Manna, G., & Comai, G. (2025). Is COVID-19 Coagulopathy a Thrombotic Microangiopathy? A Prospective, Observational Study. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26115395
Vancouver
Silingardi M, Zappulo F, Dormi A, Pizzini AM, Donadei C, Cappuccilli M, et al. Is COVID-19 Coagulopathy a Thrombotic Microangiopathy? A Prospective, Observational Study. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26115395
BibTeX
@article{Silingardi2025,
author = {Silingardi, Mauro and Zappulo, Fulvia and Dormi, Ada and Pizzini, Attilia Maria and Donadei, Chiara and Cappuccilli, Maria and Fantoni, Chiara and Zaccaroni, Stefania and Pizzuti, Valeria and Cilloni, Nicola and Tantillo, Simona and Guidi, Antonella and Mancini, Rita and La Manna, Gaetano and Comai, Giorgia},
title = {Is COVID-19 Coagulopathy a Thrombotic Microangiopathy? A Prospective, Observational Study},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26115395}
}
EUVIMED